7 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucosal #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
please refer to Table ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
#TB #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
intraocular levels of drug ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
Coccidiodomycosis #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
with ARV (see Table ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
Overview of antifungal ... • Therapeutic drug ... #valleyfever #management ... #comparison #table ... #pharmacology